Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
EMTRICITABINE vs LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural nucleosides and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and inhibits RNA-dependent DNA polymerase activity.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (lamivudine 150 mg, nevirapine 200 mg, zidovudine 300 mg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 hours; Nevirapine: 25-30 hours (single dose), 40-45 hours with multiple dosing due to autoinduction; Zidovudine: 0.5-3 hours (mean 1.1 hours). Clinical context: Dosing interval adjusted for renal/hepatic function.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: >70% unchanged in urine via glomerular filtration and active tubular secretion. Nevirapine: ~80% in urine as glucuronide conjugates and metabolites, <5% unchanged. Zidovudine: ~75% as metabolites (primarily zidovudine glucuronide) in urine, <20% unchanged.
Category C
Category A/B
Antiretroviral, NRTI
NRTI